Literature DB >> 32815253

Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin.

Mona Arbab1,2, Yu-Hui Chen3, Shana Criscitiello3, Jason Glass4, Jo Ann Fugazzotto4, Joseph H Killoran1, Glenn Hanna3, Jochen Lorch3, Robert I Haddad3, Danielle N Margalit3, Roy B Tishler3, Jonathan D Schoenfeld3.   

Abstract

BACKGROUND: Patient Reported Outcome (PRO) data comparing bolus (B-CP) with weekly (W-CP) cisplatin concurrent with radiation are lacking.
METHODS: We performed a retrospective study comparing PRO among 99 patients with head and neck radiation, 26% who received concurrent B-CP and 73% treated with W-CP.
RESULTS: W-CP patients had a higher Charlson comorbidity index (CCI) (P = .004). There were no differences in median cisplatin dose, PROs, percutaneous endoscopic gastrostomy (PEG) dependence or hospitalization between arms. Patients with a greater decline in their self-reported dysphagia score were more often PEG dependent at the end of radiation therapy (P = .03). There was also a trend toward PEG dependence with a higher maximum dysphagia score and greater change in aspiration score (P = .06). The maximum decline in white cell count and absolute neutrophil count were greater in the W-CP group (P = .04, P = .01).
CONCLUSION: Both B-CP and W-CP are well tolerated. PROs do not suggest a benefit to W-CP.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  bolus cisplatin; chemoradiation; head and neck cancer; patient reported outcome; weekly cisplatin

Mesh:

Substances:

Year:  2020        PMID: 32815253     DOI: 10.1002/hed.26432

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients.

Authors:  Michela Buglione; Daniela Alterio; Stefano Maria Magrini; Barbara Alicja Jereczek-Fossa; Marta Maddalo; Diana Greco; Marianna Alessandra Gerardi; Davide Tomasini; Ludovica Pegurri; Matteo Augugliaro; Giulia Marvaso; Irene Turturici; Andrea Guerini; Mohssen Ansarin; Luigi Spiazzi; Loredana Costa; Maria Cossu Rocca
Journal:  Radiat Oncol       Date:  2021-12-20       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.